Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs

Tomlin, J. L.; Sturgeon, C.; Pead, M. J.; Muir, Peter

doi:10.1136/vr.147.5.129

Cited by 45 publications

(27 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zoledronic inhibited the growth of OS cells and chemosentisize these cells to cisplatin [84]. The bisphosphonate drug alendronate was used to suppress bone remodeling and tumor osteolysis as a palliative treatment for two dogs with OS in a study of Tomlin et al showing positive results [85]. Bisphosphonates induce apoptosis by caspase-3-like protease activation and significantly reduce cell invasion through zinc chelation of metalloproteinase enzymes [69].…”

Section: New Drugsmentioning

confidence: 97%

Osteosarcoma treatment: state of the art

Dass

Choong

et al. 2009

Cancer Metastasis Rev

261

226

View full text Add to dashboard Cite

Osteosarcoma (OS) is a class of cancer originating from bone, mainly afflicting children or young adults. It is the second highest cause of cancer-related death in these age groups, mainly due to development of often fatal metastasis, usually in the lungs. Survival for these patients is poor despite the aggressive use of surgery, chemotherapy, and/or radiotherapy. Thus, new effective drugs and other forms of therapy are needed. This article reviews the biology and the state of the art management of OS. New experimental drugs and potential therapies targeting molecular pathways of OS are also discussed.

show abstract

Section: New Drugsmentioning

confidence: 97%

Osteosarcoma treatment: state of the art

Dass

Choong

et al. 2009

Cancer Metastasis Rev

261

226

View full text Add to dashboard Cite

show abstract

“…They are also used to manage some cases of paraneoplastic hypercalcaemia (Tomlin and others 2000, Fan 2014). …”

Section: Bisphosphonatesmentioning

confidence: 99%

Palliative care in small animal oncology

Mason¹

2016

In Practice

View full text Add to dashboard Cite

Cancer is a common diagnosis in companion animals and, increasingly, clients choose to pursue treatment for their pets. Veterinary oncology is a rapidly growing field and diagnostic and treatment options for animals with cancer are constantly improving and becoming more widely available. Treatment outcomes can be good, but in many cases definitive treatment is not an option and palliative treatment is necessary. This article explores the palliative care of dogs and cats that have been diagnosed with cancer and summarises the various treatment options, with a particular focus on quality of life and the role of communication in the decision-making process.

show abstract

“…Zoledronate has been also assessed in dog osteosarcoma. If in vivo administration of zoledronate exerts biological effects in bone (reduction of pathologic bone turnover), appears safe and has interesting clinical impact on bone pain [74][75][76], only one case report revealed possible anti-tumour effect of zoledronate [77]. However, combining N-BPs and standardised palliative therapy did not clearly show improvement of pain alleviation in a double-blind placebo-controlled trial [78].…”

Section: Osteosarcoma and Ewing's Sarcoma: Two Novel Potential Targetmentioning

confidence: 92%

Therapeutic Approach of Primary Bone Tumours by Bisphosphonates

Moriceau¹,

Ory²,

Gobin³

et al. 2010

CPD

View full text Add to dashboard Cite

Bone tumours can be dissociated in two main categories: i) primary bone tumours (benign or malignant) including mainly osteosarcoma and other sarcomas.ii)and giant cell tumour and bone metastases originate from others cancer (Breast, prostate, kidney cancer, etc). These tumours are able to destroy or/and induce a new calcified matrix. However, the first step of bone tumour development is associated with an induction of bone resorption and the establishment of a vicious cycle between the osteoclasts and the tumour growth. Indeed, bone resorption contributes to the pathogenesis of bone tumour by the release of cytokines (IL6, TNFα) which govern the bone tumour's development and which are trapped into the bone matrix. Bisphosphonates (BPs) are chemical compounds of P-C-P structure with a high affinity for bone hydroxyapatite crystals. Thus, they have been used as a carrier for radio nucleotides to develop novel approaches of bone imaging. BPs exert also indirect anti-tumour activities in vivo. Indeed, BPs directly interfere with the bone microenvironment and target osteoclasts, endothelial cells and immune cells (tumour-associated macrophages, γ9δ2 T cells). BPs induce tumour cell death in vitro and same activity is suspected in vivo. The present review summarizes the mechanisms of actions of BPs as well as their clinical interests in bone primary tumours.

show abstract

Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs

Cited by 45 publications

References 17 publications

Osteosarcoma treatment: state of the art

Osteosarcoma treatment: state of the art

Palliative care in small animal oncology

Therapeutic Approach of Primary Bone Tumours by Bisphosphonates

Contact Info

Product

Resources

About